Bosentan for pulmonary hypertension secondary to idiopathic pulmonary fibrosis
Pulmonary hypertension is a poor prognostic factor in patients with interstitial lung disease. No established treatment exists for pulmonary hypertension secondary to interstitial pneumonia. We describe the case of an 81-year-old woman with idiopathic pulmonary fibrosis (IPF), who was admitted to ou...
Main Authors: | Naomi Onda, Yosuke Tanaka, Mitsunori Hino, Akihiko Gemma |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2015-01-01
|
Series: | Respiratory Medicine Case Reports |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2213007114000586 |
Similar Items
-
Current status of bosentan for treatment of pulmonary hypertension
by: Raja Shahzad, et al.
Published: (2008-01-01) -
Role of the endothelin receptor antagonist bosentan in the treatment of patients with pulmonary hypertension
by: N A Tsareva
Published: (2013-12-01) -
Approaches to therapy for pulmonary hypertension: Role of the endothelin receptor antagonist bosentan
by: S N Avdeev
Published: (2015-09-01) -
Bosentan use in pulmonary arterial hypertension: Russian and foreign experience
by: Z S Valieva, et al.
Published: (2017-08-01) -
First clinical experience with endothelin receptor antagonist bosentan used in patients with pulmonary hypertension: results of a one-year study
by: S N Avdeev, et al.
Published: (2013-03-01)